Could measuring cortisol levels become a biological test for risk of depression in adolescent males?

shutterstock_156460130

Is it possible to work out which of two adolescents sitting before you complaining of unhappiness, which one will go home and sleep it off and which will go on to develop an episode of major depression?

Has the biological revolution in psychiatry finally come to fruition with a useful biomarker for making treatment decisions?

Is the stress system the location of the fundamental lesion in unipolar depression?

The gold standard for the diagnosis of depression is still a clinical interview, relying primarily on patients reporting depressive cognitions and behaviour. Though there have been a large number of biological abnormalities detected in depressed people, none of these have proven reliable enough to serve as a biological marker.

However, of all these findings, increased levels of the stress hormone, cortisol, is one of the most robust (though, by no means, ubiquitous). This fits with the generally accepted understanding that depression results from chronic stress in vulnerable people. Accumulating evidence suggests that this process is underpinned by a dysfunctional stress system, often manifesting in increased levels of cortisol. Cortisol also seems to have the fingerprints of the culprit in depression – possessing an ability to reduce hippocampal volume, impair neurogenesis and induce neurotoxicity in excess.

The authors of the present paper therefore set out to determine whether a measure of cortisol could improve predictions of who would develop depression over and above self-reported depressive symptoms alone.

The so-called stress hormone cortisol has been shown to reduce hippocampal volume, impair neurogenesis and induce neurotoxicity in excess

The so-called stress hormone cortisol has been shown to reduce hippocampal volume, impair neurogenesis and induce neurotoxicity in excess

Methods

They did this by examining data gathered from two cohorts of teenagers (n=660 and 1,198) who were assessed at baseline on self-report of depressive symptoms using the Moods and Feelings Questionnaire (MFQ) and had their morning salivary cortisol levels measured. The teenagers were subsequently re-assessed at intervals on the MFQ.

Their patterns of depressive symptoms and cortisol levels were used to divide the teenagers into groups using a statistical technique called latent class analysis.

The outcome measure was the presence of a DSM-IV diagnosis of depression at the end of the study period as determined by a semi-structured interview.

The authors examined whether teenagers from the the different classes had differing chances of being diagnosed with depression.

Cohort 1 was also given a cognitive test to assess their degree of overgeneral autobiographical memory (found to be more present in anxious and depressed people and thought to predict the development of depression).

Results

The authors found four classes of adolescent emerged:

Class 1: low levels of depressive symptoms and low cortisol levels
Class 2: low levels of depressive symptoms but high cortisol levels
Class 3: high levels of depressive symptoms but low cortisol
Class 4: high levels of depressive symptoms and high levels of morning cortisol

  • There was a progressive increase in the likelihood that an adolescent from Classes 2-4 would develop depression when compared to adolescents in Class 1 (expressed as an odds ratio(OR))
    • An adolescent from Class 2 had 1.6 times the chance of developing depression, as compared to an adolescent from Class 1 (OR=1.6, 95% CI 0.9 to 2.8, p=0.1) though this was not significant
    • An adolescent from Class 3 was 5.2 times as likely to develop depression (OR=5.2, 95% CI 3.2 to 8.6, p<0.0001)
    • An adolescent from Class 4 was 7.1 times as likely (OR=7.1, 95% CI 4.3 to 11.8, P<0.0001)
  • Gender played an important role in this:
    • The boys in class 4 had a much greater risk of developing depression than girls in the same group (an OR of 14.7 vs an OR of 3.5)
    • For girls, being in Class 3 carried with it an increased risk of depression than being in Class 4. This was opposite to the pattern for boys, suggesting that an increased cortisol level is a male-specific risk factor
  • The authors also found evidence of more over-generalised memory in those adolescents in Class 4 than other classes
  • Higher levels of cortisol were associated with higher levels of depression

    In boys, higher levels of cortisol were associated with higher levels of depression

Discussion

The authors conclude that the use of morning cortisol measures in adolescent boys may help stratify adolescents with depressive symptoms into those more or less likely to develop depression; with higher levels of cortisol associated with greater risk.

The authors suggest that the mechanism underlying this finding is a stress hormone-moderated process associated with impairments of autobiographical memory.

There are studies showing that boys produce higher levels of cortisol under stressful conditions and the authors speculate that boys may be more vulnerable to the neurotoxic effects of cortisol than girls.

The authors do point out that there were cases of depression that did not involve increased levels of cortisol, indicating that the process of developing depression is unlikely to involve a single pathway.

Not all cases of depression

Not all cases of depression involved increased cortisol levels

Limitations

There are a number of limitations to this study:

  • The use of a single morning cortisol measurement is of questionable reliability, with studies more commonly employing diurnal variation of cortisol or changes in cortisol in response to waking
  • Two cohorts of a quite different nature and tested in distinct ways were combined in many analyses
  • The use of latent class analysis can create the illusion of a robust separation of classes, where there is more likely to be subtle gradations between individuals
  • It is unclear the extent to what these group findings can be extrapolated to a specific individual

Conclusions

This study demonstrates some utility of a biological test in stratifying adolescent males with depressive symptoms, but questions remain to be answered before such a test could be adopted clinically.

This paper does open up further interesting avenues of research:

  • Would these classes respond to different treatments in different ways?
  • Are there further biological tests that might be combined to create a more refined prognostic tool?

It also raises the intriguing question of the gender difference between boys and girls:

  • Do the different sexes process stress differently at the level of psychology, hormonal response or in the sensitivity of their brains to stress hormones?

Answering these questions would provide a great deal of understanding about the trajectories from stress to depression.

Do males and females process

Do males and females process stress differently in terms of psychology, hormonal response and the sensitivity of our brains to stress hormones?

Link

Owens M, Herbert J, Jones PB, Sahakian BJ, Wilkinson PO, Dunn VJ, Croudace TJ and Goodyer IM. Elevated morning cortisol is a stratified population-level biomarker for major depression in boys only with high depressive symptoms. PNAS 2014 published ahead of print February 18, 2014, doi:10.1073/pnas.1318786111.

Share on Facebook Tweet this on Twitter Share on LinkedIn Share on Google+
Mark as read
Create a personal elf note about this blog
Profile photo of Mark Horowitz

Mark Horowitz

Mark Horowitz is a training psychiatrist, now working as a Clinical Research Fellow at UCL and North East London NHS Foundation Trust. He is an Associate Editor of the journal Therapeutic Advances in Psychopharmacology and has edited a collection of papers in the journal on Discontinuing Psychotropic Medication. He has a PhD in psychopharmacology and the neurobiology of depression from the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. He has an interest in rational psychopharmacology and safe deprescribing of psychiatric medications, which has been the focus of his recent work published in The Lancet Psychiatry, JAMA Psychiatry, the British Journal of Psychiatry and Schizophrenia Bulletin, as well as a forthcoming textbook on the subject.

More posts - Website

Follow me here –